公司資料
Revelation Biosciences 股價、新聞與催化劑
- 股票代碼:
- REVB
- 交易所:
- NASDAQ
- 產業:
- MedTech
- 所在地:
- United States
股票表現
0.80 USD (-1.96%)
收盤價
最後更新: 2026年10月1日
4.14M USD
市值
股價為何變動
截至 2026年10月1日，REVB 下跌 1.96%，收於 $0.8010。目前新聞監測窗口內未發現新的同公司新聞。
公司概覽
Innate Immune Modulation Company
Revelation Biosciences develops therapies intended to rebalance inflammation in acute and chronic disease. Its lead formulation activates Toll-like receptor 4 to produce a controlled innate immune response.
Gemini Lead Candidate
Gemini is a proprietary formulation of phosphorylated hexaacyl disaccharide. Rather than broadly suppressing immunity, the candidate is designed to precondition and recalibrate the inflammatory response.
Acute Kidney Injury Program
The primary development program targets acute kidney injury associated with cardiac surgery. Revelation is preparing an adaptive pivotal study intended to evaluate prevention or reduction of clinically significant kidney injury.
Clinical and Preclinical Evidence
Gemini has been evaluated in Phase 1 studies and in preclinical models of acute kidney injury, chronic kidney disease, and infection. These data support selection of dose, timing, and endpoints for later-stage development.
Manufacturing Readiness
The company has initiated GMP manufacturing of Gemini and placebo for its planned clinical program. External manufacturers, a renal-focused contract research organization, and scientific advisers support execution.
未來催化劑
- Initiation of the adaptive pivotal Phase 2/3 study of Gemini in acute kidney injury in the fourth quarter of 2026.
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。